Biogen Says Government Is Probing Its Drug Prices, Rebates, Buyer Assist Efforts

(July 22, 2016, 10:38 AM EDT) -- CAMBRIDGE, Mass. — Biotechnology company Biogen Inc. said July 21 that it received civil investigative demands on July 1 from the federal government for documents and information relating to the company’s treatment of “certain service agreements with wholesalers when calculating and reporting Average Manufacturing Prices in connection with the Medicaid Drug Rebate Program.”

Also in its Form 10-Q filed with the U.S. Securities and Exchange Commission, Biogen said that on March 4, it received a federal subpoena for documents “relating to our relationship with non-profit organizations...
To view the full article, register now.